Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Drug

Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study

Fineline Cube Sep 23, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...

Medical Device

Shanghai Sanyou Medical’s Agloe Robot Enters Chinese NMPA Special Review for Innovative Spine Devices

Fineline Cube Sep 23, 2025

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085) announced that its affiliate Agloe Medical Technologies has...

Company Drug

Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR

Fineline Cube Sep 23, 2025

Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau‑protein antibody etalanetug (E2814) has...

Company Deals Drug

Pfizer to Acquire Metsera for $4.9 B, Expanding Its Obesity & Cardiometabolic Pipeline

Fineline Cube Sep 23, 2025

Pfizer Inc. (NYSE: PFE) announced today that it will acquire Metsera, Inc. (NASDAQ: MTSR), a...

Company Drug

Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B

Fineline Cube Sep 23, 2025

Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...

Policy / Regulatory

National Healthcare Security Administration Announces Nationwide Pilot for Real‑World Medical‑Insurance Value Evaluation

Fineline Cube Sep 23, 2025

The National Healthcare Security Administration (NHSA) today issued a notice outlining a multi‑city pilot program...

Company Drug

Huadong Medicine Secures FDA IND Approval for HDM2017 ADC

Fineline Cube Sep 23, 2025

Huadong Medicine Co., Ltd. (SHE: 000963) announced today that the U.S. Food and Drug Administration...

Company Drug

Sichuan Kelun‑Biotech’s A400 Receives NDA Acceptance in China

Fineline Cube Sep 23, 2025

Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the Center for Drug Evaluation...

Company Drug

Visen Pharmaceuticals Secures Hainan Approval for Palopegteriparatide

Fineline Cube Sep 23, 2025

Visen Pharmaceuticals (HKG: 2561) announced today that its innovative drug palopegteriparatide (TransCon PTH) has received official...

Company Drug

Stone Pharmaceuticals Launches CS2009 Phase II Trial in Australia

Fineline Cube Sep 23, 2025

CStone Pharmaceuticals (HKG: 2616) announced today that the first patient has been dosed in Australia...

Company Drug

Nanjing Leads Biolabs Secures FDA IND for LBL‑047, a First‑In‑Class Bispecific Fusion Protein

Fineline Cube Sep 23, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced today that the U.S. Food and Drug...

Company Deals

China’s Insilico, Mabwell, and Chemexpress Forge AI‑Driven ADC Collaboration

Fineline Cube Sep 22, 2025

Insilico Medicine, a global leader in generative AI‑driven drug discovery, announced a strategic partnership with...

Policy / Regulatory

NHSA Completes 2025 Drug Negotiation Review; CAR‑T Therapies Clear the Hurdle

Fineline Cube Sep 22, 2025

The National Healthcare Security Administration (NHSA) announced today that the expert review for the 2025...

Company Drug

Shenzhen Salubris Submits NMPA NDA for SAL003, a Once‑Monthly Anti‑PCSK9 Biologic

Fineline Cube Sep 22, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced that it has filed a New Drug...

Company Deals

Biogen Acquires Alcyone Therapeutics to Drive ThecaFlex DRx Implant Development

Fineline Cube Sep 22, 2025

Biogen Inc. (NASDAQ: BIIB) announced the acquisition of Massachusetts‑based Alcyone Therapeutics. The deal centers on...

Company Drug

Henlius Organon Secure EU Marketing Approval for BILDYOS and BILPREVDA Denosumab Biosimilars

Fineline Cube Sep 22, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Commission...

Company Drug

Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes

Fineline Cube Sep 22, 2025

Innovent Biologics Ltd. (HKG: 1801) announced that its mazdutide injection (IBI362) has received its second...

Company Deals

AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development

Fineline Cube Sep 22, 2025

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively “AusperBio”) announced that it has closed...

Company Deals

Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party

Fineline Cube Sep 22, 2025

Pfizer Inc. (NYSE: PFE) and Arvinas, Inc. (NASDAQ: ARVN) announced that they are stepping back...

Company Drug

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic

Fineline Cube Sep 19, 2025

Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA)...

Posts pagination

1 … 43 44 45 … 609

Recent updates

  • ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination
  • Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors
  • U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss
  • Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
  • Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Company Drug

U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.